Abstract

Mutations in LRRK2 cause a dominantly inherited form of Parkinson’s disease (PD) and are the most common known genetic determinant of PD. Inhibitor-based therapies targeting LRRK2 have emerged as a key therapeutic strategy in PD; thus, understanding the consequences of inhibiting the normal cellular functions of this protein is vital. Despite much interest, the physiological functions of LRRK2 remain unclear. Several recent studies have linked the toxicity caused by overexpression of pathogenic mutant forms of LRRK2 to defects in the endolysosomal and autophagy pathways, raising the question of whether endogenous LRRK2 might play a role in these processes. Here, we report the characterization of multiple novel ethyl methanesulfonate (EMS)-induced nonsense alleles in the Drosophila LRRK2 homolog, lrrk. Using these alleles, we show that lrrk loss-of-function causes striking defects in the endolysosomal and autophagy pathways, including the accumulation of markedly enlarged lysosomes that are laden with undigested contents, consistent with a defect in lysosomal degradation. lrrk loss-of-function also results in the accumulation of autophagosomes, as well as the presence of enlarged early endosomes laden with mono-ubiquitylated cargo proteins, suggesting an additional defect in lysosomal substrate delivery. Interestingly, the lysosomal abnormalities in these lrrk mutants can be suppressed by a constitutively active form of the small GTPase rab9, which promotes retromer-dependent recycling from late endosomes to the Golgi. Collectively, our data provides compelling evidence of a vital role for lrrk in lysosomal function and endolysosomal membrane transport in vivo, and suggests a link between lrrk and retromer-mediated endosomal recycling.

Highlights

  • Parkinson’s disease (PD) is a common and devastating neurodegenerative movement disorder

  • Implications and future directions These results demonstrate the crucial role played by the Drosophila leucine-rich repeat kinase 2 (LRRK2) homolog in lysosomal transport and in cargo trafficking to the lysosome in the endocytic pathway

  • The findings suggest that efforts to target LRRK2 activity therapeutically will need to be aimed at mutant LRRK2 alleles

Read more

Summary

Introduction

Parkinson’s disease (PD) is a common and devastating neurodegenerative movement disorder. Received 28 May 2014; Accepted 25 September 2014 kinase 2 (LRRK2) gene is an important therapeutic target for PD because it is the most common known genetic determinant of the disease (Dawson et al, 2010; Kett and Dauer, 2012). LRRK2 encodes a large multi-domain protein characterized by leucine-rich repeats, a GTPase domain and a kinase domain (Bosgraaf and Van Haastert, 2003). The cellular functions of LRRK2 remain unclear because it has been linked to multiple diverse cellular processes, including mitochondrial function (Smith et al, 2005), regulation of transcription (Kanao et al, 2010) and translation (Gehrke et al, 2010; Imai et al, 2008; Martin et al, 2014), Golgi protein sorting (Sakaguchi-Nakashima et al, 2007), apoptosis (Ho et al, 2009), and regulation of the dynamics of actin (Jaleel et al, 2007; Parisiadou et al, 2009) and microtubules (Gandhi et al, 2008; Gillardon, 2009; Kett et al, 2012; Lin et al, 2009)

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.